ArticleBMC cancer2026
Identification of novel exosomal miRNAs and their role in diagnosis and prognosis of triple negative breast cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exosomes and Triple-Negative Breast Cancer: Current Knowledge and Clinical Significance.International journal of molecular sciences · 2026Pooled it
- Autophagy-associated exosomal microRNAs in triple-negative breast cancer: a discovery-phase study.Molecular biology reports · 2026Article
- The Multifaceted Role of Extracellular Vesicles in Triple Negative Breast Cancer.International journal of molecular sciences · 2026Review
- The functional dichotomy of exosomal microRNAs in TNBC: implications for chemoresistance and integrated theranostics.Molecular biology reports · 2026Review
- Review
- Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a clinically aggressive subtype characterized by poor prognosis and limited therapeutic options. Exosomal microRNAs (miRNAs), enclosed within secretory vesicles, have emerged as promising non-invasive biomarkers for cancer detection and disease monitoring. In this study, we identify a panel of five exosomal miRNAs: hsa-miR-6803, hsa-miR-1180, hsa-miR-4728, hsa-miR-1915, and hsa-miR-940, that are consistently overexpressed in TNBC cells, stem-like subpopulations, and patient tumor tissues. Integrated meta-analysis of public datasets combined with in-vitro validation revealed that elevated expression of these miRNAs correlates with poor overall survival. Functional assays further demonstrated that hsa-miR-1180 and hsa-miR-4728 enhance TNBC cell migration and invasion, implicating them in key oncogenic pathways such as Wnt, Notch, and EGFR. The consistent enrichment of these miRNAs in exosomes underscores their potential as exploratory biomarkers for future liquid-biopsy-based applications. To our knowledge, this discovery-phase investigation is the first to associate this exosomal miRNA panel with TNBC and its stem-like subpopulations, providing a preliminary framework for subsequent mechanistic and translational validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.